AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9477042
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (2 tab/day)
Trial: 3060511
Drug: Topical glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticosteroids (budesonide, 100 micrograms in each nasal cavity every 12 hours)
Trial: 28459795
Drug: Nordic hamstring
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordic hamstring exercise (NHE) program, 4 weeks, twice a week, 3 sets of 6-10 repetitions
Trial: 28628003
Drug: FCM-miniR (fludarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCM-miniR (fludarabine, cyclophosphamide, mitoxantrone, and low-dose rituximab)
Trial: 16735174
Drug: Metabolite ratio
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolite ratio (citrate/(choline+creatine)) and ADC values in patients with PSA >20 ng/ml (Group II)
Trial: 16735174
Drug: Metabolite ratio
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolite ratio and ADC values in patients with PSA 4-20 ng/ml (Group III)
Trial: 8626878
Drug: Low-dose amlodipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amlodipine 2.5 mg daily
Trial: 8626878
Drug: Low-dose benazepril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose benazepril 10 mg daily
Trial: 8626878
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amlodipine 2.5 mg and benazepril 10 mg daily
Trial: 30642308
Drug: Early medication
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early medication change (EMC) strategy with immediate switch to high doses of venlafaxine XR
Trial: 30642308
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) with continued escitalopram until day 28
Trial: 28545804
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate (FF) 50 µg once daily in the evening
Trial: 28545804
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone Furoate (FF) 50 µg
Trial: 23712210
Drug: CBT-ERT (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-ERT (Cognitive Behavioral Therapy enriched with Emotion Regulation Training)
Trial: 18955525
Drug: OPT-80 50
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-80 50 mg
Trial: 18955525
Drug: OPT-80 100
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-80 100 mg
Trial: 18955525
Drug: OPT-80 200
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPT-80 200 mg
Trial: 8174716
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) plus oral contraceptive (OC) containing cyproterone acetate
Trial: 20627691
Drug: Standardized monofilament
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized monofilament 10 g (pressure)
Trial: 16723364
Drug: Ofloxacin plus
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin plus metronidazole (ofloxacin 400 mg twice daily + metronidazole 500 mg twice daily)
Trial: 8971305
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days
Trial: 8971305
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days
Trial: 8971305
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days
Trial: 8971305
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days
Trial: 8971305
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days
Trial: 8971305
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days
Trial: 1595789
Drug: Buserelin acetate
RxNorm normalized name: buserelin acetate
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin acetate (400 micrograms intranasal three times daily for 6 months)
Trial: 30346481
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg orally twice daily for ≤3 years (minimum 1 year unless recurrence, second primary malignancy, significant toxicity, or consent withdrawal)
Trial: 25765462
Drug: Mesalazine 2
RxNorm normalized name: mesalazine 2 GM per 59 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine 2 g twice daily
Trial: 24991045
Drug: Buttermilk drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buttermilk drink containing 1.5 lutein-rich egg yolks daily for 1 year
Trial: 18384442
Drug: Budesonide (1000-mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1000-mug dose via dry powder inhaler)
Trial: 18384442
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (1000-mug dose via dry powder inhaler)
Trial: 9915317
Drug: Target effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target effect compartment concentration of propofol (5.4 microg/ml)
Trial: 9915317
Drug: Target central
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target central compartment concentration of propofol (5.4 microg/ml)
Trial: 7005134
Drug: Levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5 mg/kg, two days a week, for eight weeks
Trial: 31266489
Drug: Glycopyrrolate 15.6
RxNorm normalized name: GLYCOPYRROLATE 15.6MCG CAP,INHL,60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 15.6 μg twice daily
Trial: 29724638
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine 9.1 mg
Trial: 17284138
Drug: Intramuscular aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular aripiprazole 9.75 mg
Trial: 25068233
Drug: Isotretinoin therapy
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin therapy (20-30 mg/day) for 6 months associated with dietary supplement (twice a day)
Trial: 25068233
Drug: Isotretinoin therapy
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin therapy (20-30 mg/day) for 6 months
Trial: 9213879
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride (100 mg twice a day for 10 days)
Trial: 9213879
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-steroidal anti-inflammatory drugs for rheumatoid arthritis, paracetamol for OA and vertebrogen syndrome)
Trial: 1927946
Drug: Soluble aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin, 100 mg/day
Trial: 6350247
Drug: Carbohydrate feeding
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate feeding (glucose polymer solution)
Trial: 25029557
Drug: Isotonic solution
RxNorm normalized name: Isotonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic solution (Gatorade®)
Trial: 23629739
Drug: Monitoring weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monitoring weekly after 1 month
Trial: 19808309
Drug: HeartMate I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeartMate I LVAD implantation at centers performing <=4 DT implants
Trial: 19808309
Drug: HeartMate I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeartMate I LVAD implantation at centers performing >9 DT implants
Trial: 15155328
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg succinylcholine
Trial: 15155328
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg succinylcholine
Trial: 1994867
Drug: Stanozolol treatment
RxNorm normalized name: Stanozolol
DrugBank: Stanozolol (DB06718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanozolol treatment in primary Raynaud's phenomenon
Trial: 1994867
Drug: Stanozolol treatment
RxNorm normalized name: Stanozolol
DrugBank: Stanozolol (DB06718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stanozolol treatment in systemic sclerosis
Trial: 6500169
Drug: Ibuprofen (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (7 mg/kg of body-weight)
Trial: 6500169
Drug: Aspirin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (15 mg/kg of body-weight)
Trial: 31508504
Drug: Alternative solution
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative solution of polyphyletic bradoriids
Trial: 29886423
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg and Nifedipine slow release 30 mg
Trial: 1463157
Drug: 0.06 to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 to 0.08 mg intrathecal morphine
Trial: 1463157
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without morphine
Trial: 22721546
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to medication
Trial: 12683740
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UV photo and photoaging information
Trial: 10222548
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg qPM
Trial: 2064494
Drug: Nutritional-hygienic intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional-hygienic intervention plus antihypertensive medication (diuretic, beta-blocker, alpha 1-antagonist, calcium antagonist, or ACE inhibitor)
Trial: 6242795
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin infusion (CIVII)
Trial: 18631958
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg daily (background therapy)
Trial: 15114097
Drug: Induction (T-cell-depleting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction (T-cell-depleting and interleukin-2 receptor antibodies)
Trial: 15114097
Drug: T-cell-depleting antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell-depleting antibody induction
Trial: 15114097
Drug: Anti-interleukin-2 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-interleukin-2 receptor antibodies
Trial: 8224951
Drug: Argon laser
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon laser treatment (ALT)
Trial: 8224951
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment (DLT)
Trial: 27663118
Drug: Immediate TMS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate TMS treatment (n=7)
Trial: 27663118
Drug: Delayed TMS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed TMS treatment (n=3)
Trial: 25420793
Drug: Intradermal sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal sodium stibogluconate (SSG)
Trial: 17432693
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (Ginaton) 0.5 mg/kg
Trial: 17432693
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (St. Thomas' cardioplegic solution only)
Trial: 17469410
Drug: Transendoscopic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transendoscopic saline injection with or without epinephrine + coaptive bipolar electrocoagulation or heater probe
Trial: 17469410
Drug: Antisecretory agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory agents at high doses
Trial: 12190367
Drug: homocysteine-lowering therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homocysteine-lowering therapy with folic acid (1 mg/d), vitamin B12 (400 micro g/d), and vitamin B6 (10 mg/d) (n = 272)
Trial: 12190367
Drug: homocysteine-lowering therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6
Trial: 10202868
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone (200 mg three times daily)
Trial: 10202868
Drug: IM progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM progesterone (50 mg daily)
Trial: 7795309
Drug: N-acetylcystein (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcystein (NAC) administration as a bolus of 100 mg/kg followed by a continuous infusion of 20 mg/kg/h during cardiopulmonary bypass (CPB)
Trial: 101223
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg, 50 mg, and 100 mg twice daily
Trial: 101223
Drug: Atenolol twice
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol twice daily
Trial: 101223
Drug: Atenolol (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (once or twice daily)
Trial: 27599598
Drug: FSC 50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 50/250 μg via Rotacaps/Rotahaler
Trial: 27599598
Drug: FSC 50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 50/250 μg via Diskus
Trial: 27599598
Drug: FSC 50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSC 50/250 μg via Rotacaps/Rotahaler and Diskus
Trial: 24147895
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg day(-1)) and zinc sulphate (220 mg day(-1))
Trial: 24147895
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg day(-1))
Trial: 24147895
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (220 mg day(-1))
Trial: 22209625
Drug: Capsaicin (TRPV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (TRPV1 agonist)
Trial: 22209625
Drug: Cinnamaldehyde (TRPA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamaldehyde (TRPA1 agonist)
Trial: 14525630
Drug: Intrapulmonary percussive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapulmonary percussive ventilation (IPV) during nebulizer treatment
Trial: 10770541
Drug: GM‐CSF (sargramostim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF (sargramostim) 250 microg subcutaneous injections three times per week for 24 weeks
Trial: 1900410
Drug: Intravenous etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous etidronate disodium (136 patients)
Trial: 27112319
Drug: Fear of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fear of Recurrence Therapy (FORT) intervention
Trial: 22777592
Drug: Probiotic lactobacilli
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lactobacilli vaginal tablets (L. brevis CD2, L. salivarius subsp. salicinius, L. plantarum)
Trial: 22777592
Drug: Vaginal pH
RxNorm normalized name: Azo Vaginal pH Test Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal pH tablet (active comparator)
Trial: 22777592
Drug: Probiotic lactobacilli
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lactobacilli vaginal tablets
Trial: 12183688
Drug: d‐amphetamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (30 mg oral dose)
Trial: 9990363
Drug: Calcipotriol (Dovonex)
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol (Dovonex) ointment (50 micrograms/g) twice daily for up to 3 months
Trial: 3419842
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine (2 mg or 4 mg) and pentazocine (15 mg or 30 mg)
Trial: 3419842
Drug: Morphine (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2, 4, 8 or 16 mg)
Trial: 3419842
Drug: Pentazocine (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (15, 30 or 60 mg)
Trial: 31639063
Drug: Low-dose haMPCs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose haMPCs (1.0 × 10^7 cells)
Trial: 31639063
Drug: Mid-dose haMPCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose haMPCs (2.0 × 10^7 cells)
Trial: 31639063
Drug: High-dose haMPCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose haMPCs (5.0 × 10^7 cells)
Trial: 31639063
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of haMPCs
Trial: 30077556
Drug: Midazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.25 mg kg−1) prior to alfaxalone (0.5 mg kg−1)
Trial: 30077556
Drug: Alfaxalone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (0.5 mg kg−1) followed by midazolam (0.25 mg kg−1)
Trial: 30077556
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV prior to alfaxalone administration (Control group)
Trial: 17324531
Drug: Temozolomide (Temodar)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (Temodar) chemotherapy
Trial: 17324531
Drug: Chemical hypoxic
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical hypoxic cell sensitizers or carbon ion therapy
Trial: 15998892
Drug: PSA cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL
Trial: 9719123
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (as in arm B) in consecutive patients after December 1993
Trial: 30977301
Drug: LCIG-HV formulation
RxNorm normalized name: Perox HV-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCIG-HV formulation
Trial: 30977301
Drug: LCIG-LV formulation
RxNorm normalized name: LV-FAH
DrugBank: LV-FAH (DB17686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCIG-LV formulation
Trial: 21494175
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine (2 doses, 6 to 9 months apart)
Trial: 21494175
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine coadministered with DTaP and Hib vaccines (2 doses of HAV vaccine, 6 to 9 months apart)
Trial: 21494175
Drug: DTaP and
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP and Hib vaccines followed by HAV vaccine (DTaP and Hib at 15 months, HAV 30 days later, second dose of HAV 7 to 10 months after DTaP+Hib)
Trial: 19782785
Drug: Beta-blockers, aldosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers, aldosterone antagonists, CRT therapy